Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

The main objectives of the open label dosing and dosimetry study are to confirm the maximum tolerated dose of Cotara, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In both ongoing clinical trials, Cotara is delivered using convection-enhanced delivery (CED), a method developed by the U.S. National Institutes of Health that targets the specific tumor site in the brain.

"We believe the data generated from this dosimetry trial will be an important and necessary part of our Cotara regulatory package as we continue to advance the program," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "The trial design the regulatory authorities asked us to implement was necessarily complex and therefore challenging to enroll, requiring a significant commitment from both patients and the participating health care institutions. We are grateful for their successful efforts and our plan is now to expand the ongoing 40-patient Phase II Cotara GBM trial to these clinical sites, which should help expedite timely completion of the ongoing Phase II clinical trial."

Interim data from the dosimetry trial presented at the Society of Nuclear Medicine 2009 Annual Meeting in June showed that in patients dosed in the first two cohorts of the study, the concentration of Cotara in brain tumors was on average more than 300-fold higher than in other normal organs. In addition, these patients had all either met or exceeded the expected median survival time for recurrent GBM patients. Interim data from a Phase II study of GBM patients who have experienced a first relapse was presented at the XIV World Congress of Neurological Surgery in September. It highlighted a subset of 10 GBM patients and included follow-up durations ranging from seven weeks to over 73 weeks, showing an interim median recurrence-free
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The Alliance ... a multi-stakeholder non-profit collaborative building a global system ... research, today announced Phase 3 of its Site ... , Amir H. Kalali, Vice-President, Global Head, Neuroscience ... President, Compliance and Quality Integration (CQI) Consulting will ...
(Date:9/16/2014)... can harvest energy from jaw movements has been created ... is hoped that the device can generate electricity from ... small-scale implantable or wearable electronic devices, such as hearing ... , The first results of the device,s performance have ... Smart Materials and Structures . , Jaw movements ...
(Date:9/16/2014)... to cars and flashlights, batteries play an important ... constantly are seeking ways to improve battery life ... a water-based solution, researchers at the University of ... nuclear battery that could be used for many ... automobiles and also in complicated applications such as ...
(Date:9/16/2014)... Sept. 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... has been shown to be effective in animal models ... alternative to intravenous infusions that could pave the way ... were presented yesterday at the Heart Failure Society of ... Las Vegas . The ...
Breaking Biology Technology:Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... Popular Emergency Department Information, System Also Includes Embedded Web ... ... DALLAS, Oct. 24 T-System, Inc., the leading provider of,clinical ... announced the release of The T SystemEV(R),2.6.3, the newest upgrade to ...
... JERUSALEM, October 24 IDenta Corp. (Other,OTC: IDTA.PK) ... penetration of the United States and Oversees markets., ... Corporation (Encino,CA) and IDenta Corporation continues, has resulted ... quarters of 2008. Accutest(R) IDenta sales,have increased significantly ...
... held October 29-31 at the Palace Hotel, San,Francisco, ... Group, the world,s,marketplace for expertise, and the Biotechnology ... the Seventh Annual BIO Investor,Forum. Featured therapeutic panels ... consultants along with executives from public and,private equity ...
Cached Biology Technology:T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture 2T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 2Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 3
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] After decades of decline, ... Cod,s saltmarshes. To the eye, the marsh in those ... clear that a key service of the marsh ... aesthetics back but the ecosystem function hasn,t come back," ... and senior author of the study in the journal ...
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... cell factor overexpressed both in brain tumor cells and ... inducing angiogenesis. The research study, published in the April ... cells and surrounding tissues and may have substantial significance ... the most lethal types of tumor, malignant gliomas. ...
... play an important role in regulating blood flow in ... assumptions underlying today's most sophisticated brain imaging techniques and ... understanding Alzheimer's disease. , In a paper to appear ... available on-line, scientists at the University of Rochester Medical ...
... the Virginia Bioinformatics Institute at Virginia Tech have ... range of microbial genome sequences. , The VBI ... recent article published in Nucleic Acids Research (Vol.34, ... the plant pathogens Phytophthora sojae and Phytophthora ramorum. ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Blood flow in brain takes a twist, affecting views of Alzheimer's 2Blood flow in brain takes a twist, affecting views of Alzheimer's 3Virginia Bioinformatics Institutes launches microbial database 2